Introduction {#section5-2050312120910353}
============

Extracorporeal membrane oxygenation (ECMO) is a life support procedure that has been used around the world since the 1970s.^[@bibr1-2050312120910353]^ During this life support procedure, the cardiorespiratory function is substituted by a machine placed next to the patient's bed. Its use is indicated when there is severe respiratory or cardiorespiratory failure that does not respond to conventional treatments.^[@bibr2-2050312120910353]^

Since the 1970s, ECMO has been used as a therapeutic alternative at most tertiary-care hospitals in the United States and Europe; however, in Mexico its use was not established until 2013.^[@bibr3-2050312120910353]^ In Latin American countries, some investigation has been conducted in which the use of this procedure is reported, but with a high mortality rate.^[@bibr4-2050312120910353]^ After 2013, the pediatric ECMO program was initiated at the Pediatric Intensive Care Unit of Christus Muguerza High Specialty Hospital in Monterrey, Nuevo Leon, Mexico.^[@bibr5-2050312120910353]^

The main purpose of this procedure is to offer life support to patients with cardiorespiratory failure when conventional treatments have failed. To achieve this goal, the blood is drained into a machine placed at the patient's bed side, oxygenated, heated, and finally returned to the patient.^[@bibr6-2050312120910353],[@bibr7-2050312120910353]^

This circulation occurs through polyvinyl chloride tubes whose diameter varies depending on the patient's weight. First, this tube is connected to a double-lumen or venous cannula, depending on the type of ECMO. Then, the old blood travels through this tube and reaches "the bladder," a type of venous reservoir. The blood then passes to the pump, a system that acts as a heart, and completes the programmed revolutions per minute; after passing through the pump, the blood reaches a membrane oxygenator or artificial lung, where O~2~ is added to the blood and CO~2~ is removed; finally, the blood passes through a heat exchanger, where it reaches an adequate temperature before returning to the patient, through the double-lumen of a venous cannula, or through an arterial cannula.^[@bibr8-2050312120910353]^

In general, two types of ECMO are recognized, according to the blood vessel to which it is connected: venoarterial and venovenous.

Venoarterial extracorporeal membrane oxygenation {#section6-2050312120910353}
------------------------------------------------

In the venoarterial extracorporeal membrane oxygenation (V-A ECMO) system, a cannula is generally placed in the common right femoral vein for the extraction and an arterial cannula is generally placed in the right femoral artery for the infusion. The tip of the venous femoral cannula must be close to the union of the inferior vena cava and the right atrium, while the tip of the femoral artery cannula is maintained in the iliac artery. In adults, access to the femoral artery is preferred because insertion is simpler. A variation of this system occurs when the catheters are placed in central locations which may occur when the first catheter is placed in the right atrium and the second one is placed in the ascending aorta.^[@bibr9-2050312120910353]^

The purpose of this study is to describe the findings during the first years using V-A ECMO in pediatric patients after cardiovascular surgery at Christus Muguerza High Specialty Hospital in Monterrey, Mexico.

Materials and methods {#section7-2050312120910353}
=====================

This was a retrospective, observational, and descriptive study. The files of pediatric patients with post-operative congenital heart defects after cardiovascular surgery who were treated with V-A ECMO from January 2013 to December 2015 were reviewed.

Population {#section8-2050312120910353}
----------

Monterrey, Mexico, is the largest city in northern Mexico and has the best hospitals. It has a population of 5 million, and four private and three public hospitals with pediatric intensive care units, but only Christus Muguerza has experience with ECMO. This study shows the first experiences treating cardiovascular post-operated pediatric patients with V-A ECMO in the Pediatric Intensive Care Unit of Christus Muguerza High Specialty Hospital from January 2013 to December 2015.

### Selection criteria {#section9-2050312120910353}

All files of complex congenital heart surgery post-operative patients who were treated with V-A ECMO were included, regardless of their age, gender, or reason for the heart surgery.

### Exclusion criteria {#section10-2050312120910353}

All files of patients with chromosomic alterations or congenital coagulation disorders were excluded from the study.

### Elimination criteria {#section11-2050312120910353}

All files with incomplete or illegible data were eliminated.

Procedures {#section12-2050312120910353}
==========

This protocol was first registered with the research and bioethics committees. Once registration was obtained, an authorization was requested from the person in charge of the hospital's clinical files, who assigned a person to assist in locating the files with the diagnoses.

Only 11 files that met the selection criteria were located, and therefore we decided to include all the files. The data were collected directly from the files. The files were located according to the patient's diagnosis and previous registration at the intensive care unit. These data were collated with the records of the intensive care unit to confirm their consistency.

The data were obtained from the files through direct observation and with the assistance of two medical school students. All data were registered in an Excel database.

Sample and sampling {#section13-2050312120910353}
-------------------

Considering that only 11 newborn records met the selection criteria, we decided not to perform a sampling and no sample size calculation was performed. Then, we decided to conduct a census study including files of all patients. The data were collected directly from the files. The files were located according to the patient's diagnosis and previous registration at the intensive care unit. These data were collated with the records of the intensive care unit to confirm their consistency.

Data analysis {#section14-2050312120910353}
-------------

All data were recorded on an Excel spreadsheet designed especially for this project and statistical analysis was performed with the assistance of SPSS v18. Descriptive statistics were used exclusively, where the qualitative variables were expressed as frequencies and the quantitative variables were reported as mean and standard deviation.

Study variables {#section15-2050312120910353}
---------------

Given that this is a descriptive study, all variables were considered independently; there was no cross-referencing between variables since this is a study limited in its sample size and it is not the objective of this research. The operationalization of variables is shown in [Table 1](#table1-2050312120910353){ref-type="table"}.

###### 

System of variables used in this study.

![](10.1177_2050312120910353-table1)

  Variable                     Definition                                                        Operative definition                                         Scale
  ---------------------------- ----------------------------------------------------------------- ------------------------------------------------------------ -----------------------------------
  Age                          Time the person has lived since birth                             Months of life the person has left according to their file   Discreet quantitative (months)
  Gender                       Physical traits that differentiate a male from a female           According to the file data                                   Binomial: masculine or feminine
  Diagnosis                    Name of the disease affecting a person                            Disease for which person underwent surgery                   Nominal: name of the disease
  Surgical risk scale          Risk of mortality in surgical patients                            According to the RACHS-1 scale                               Discreet quantitative from 1 to 6
  ECMO time span               Length of time a person receives ECMO life support                According to the time registered in the file                 Continuous quantitative (minutes)
  Time of aortic impingement   Time that the aorta remained impinged                             Time of impingement registered in the file                   Continuous quantitative (minutes)
  Complications                Presence of a disease secondary to another disease or procedure   Complications registered in the file                         Nominal
  Mortality                    Death                                                             Registered deaths                                            Binomial: yes/no
  Cause of death               Reason the person died                                            Cause of death registered in the file                        Nominal

RACHS-1: The Risk Adjustment for Congenital Heart Surgery; ECMO: extracorporeal membrane oxygenation.

Ethical considerations {#section16-2050312120910353}
----------------------

This project was registered with the bioethics and research committee of the Christus Muguerza High Specialty Hospital in Monterrey, Mexico, and the University of Monterrey (ref.: 02052019-CI). Waiver for not requesting informed consent was also obtained (ref.: 16082019-a-C-CI). All patient data were handled confidentially.

Outcomes {#section17-2050312120910353}
--------

Eleven patients were reviewed, of which seven (63.7%) were neonates and four (36.3%) were of pediatric age. Of those 11 patients, 7 (63.7%) were male and the rest were female. The diagnoses were very diverse but the most common were transposition of great vessels, pulmonary stenosis (EP), and tetralogy of Fallot. Average surgical risk was 3.7 on the RACHS-1 (The Risk Adjustment for Congenital Heart Surgery) scale. The main diagnoses for which the patients were surgically intervened are shown in [Table 2](#table2-2050312120910353){ref-type="table"}.

###### 

Distribution of patients according to their sociodemographic data, diagnoses, and surgical risk.

![](10.1177_2050312120910353-table2)

  Gender   Diagnosis                   Age (days)   Weight (kg)   RACHS-1
  -------- --------------------------- ------------ ------------- ---------
  F        Severe pulmonary stenosis   2            2.6           3
  F        Multiple IVC                270          5.1           2
  F        APVR                        330          9.2           3
  M        TGV + EP                    5            2.7           4
  M        TGV                         4            3.5           4
  M        TGV                         2            3.1           4
  F        Tetralogy of Fallot         7            3             4
  M        LHHS                        5            2.7           6
  M        Tetralogy of Fallot         575          8             3
  M        TGV + IVC + EP              15           4.5           4
  M        Pulmonary atresia           425          8.5           4

RACHS-1: The Risk Adjustment for Congenital Heart Surgery; IVC: interventricular communication; APVR: anomalous pulmonary venous return; TGV: transposition of the great vessels; EP: Pulmonary stenosis; LHHS: Left heart hypoplastic syndrome.

All patients were treated with a V-A ECMO Marquet© circuit with Bioline cover, and Quadrox© oxygenating pediatric membrane with centrifugal Rotaflow system.

An ultrasound was performed on all neonates prior to the procedure to rule out cerebral hemorrhage prior to ECMO. The cannulation sites were central in all patients, leaving the chest exposed and covered with sterile plastic. During the procedure, SvO~2~, hematocrit, and post-membrane saturation were monitored continuously. All patients were treated in the same way during the procedure with commencement of anticoagulation with heparin until activated coagulation time (ACT) was \<300 s and partial thromboplastin time (PTT) \<80 s. ACT was determined every 3 h, prothrombin time (PT) PTT and platelets every 6 h, and XA anti-factor and antithrombin III every 24 h; homeostasis was maintained according to ELSO (Extracorporeal Life Support Organization) guidelines. Blood flows were maintained between 100 and 150 mL/kg/h with pulmonary flow at rest and volume-controlled ventilation (CMV). All patients' vital signs were monitored, including hydric balance, diuresis, and near-infrared tissue spectroscopy (NIRS) to monitor tissue oxygenation. All patients were treated with analgesia and sedation. Hemofiltration or hemodiafiltration was performed on 54.5%, as applicable. A pediatric cardiologist performed an echocardiogram every 24 h to measure ejection fraction, ventricular function, and response to flow diminishment. The criteria for weaning were handled in consensus according to clinical data from each patient's echocardiogram.

The time span for extracorporeal circulation was 266.4 ± 111.3 min and the average time of aortic impingement was 141.0 ± 61.2 min. The main indication for treating a patient with V-A ECMO was failure in the extraction of extracorporeal circulation. The site of placement was 63.7% in the operating room and the rest within the same intensive therapy unit.

Survival rate was 54.5% and average time span was 6.3 ± 4.9 days. The main complications were sepsis (36.3%), multi-organ dysfunction syndrome (MODS; 27.3%), acute renal failure (ARF; 18.8%), and severe cerebral hemorrhage (9.1%). The main causes of death were MODS, 27.3%, ARF, and cerebral hemorrhage, both with 18.8% ([Table 3](#table3-2050312120910353){ref-type="table"}). All patients who died had undergone surgery in the operating room. In addition, all patients who remained on ECMO for more than 4 days died. Surviving patients had an average stay in ECMO of 3.8 ± 0.4 days, while those who finally died had an average stay of 9.4 ± 6.2 days.

###### 

Results according to extracorporeal circulation (ECC) times and time span in ECMO (days).

![](10.1177_2050312120910353-table3)

  ECC time (min)   ECMO setup       ECMO time span (days)   Complications                    Result
  ---------------- ---------------- ----------------------- -------------------------------- ----------
  128              Operating room   10                      ARF, S, myocardial dysfunction   Death
  107              PICU 72 h        4                       No                               Survival
  373              PICU 72 h        3                       No                               Survival
  392              Operating room   4                       No                               Survival
  338              Operating room   3                       ARF, S, cerebral hemorrhage      Death
  270              Operating room   3                       S, MODS                          Death
  340              Operating room   16                      MODS                             Death
  140              PICU 3 h         4                       No                               Survival
  121              PICU 72 h        4                       No                               Survival
  357              Operating room   15                      S, MODS                          Death
  305              PICU 48 h        4                       No                               Survival

ECMO: extracorporeal membrane oxygenation; ARF: acute renal failure; MODS: multi-organ dysfunction syndrome: S: sepsis; PICU: pediatric intensive care unit.

Discussion {#section18-2050312120910353}
==========

In this investigation, we are presenting our growing experience treating cardiovascular post-operated pediatric patients with V-A ECMO. Even in the context of a city with great economic growth, it is quite difficult to find patients or insurance with economic capacity to cover the costs generated by the ECMO. Hospital costs range from US\$42,554 to US\$537,554.^[@bibr10-2050312120910353],[@bibr11-2050312120910353]^

For these reasons, we have only obtained a small sample. However, in spite of that, we decided to conduct this study to compare our results with what was reported in the world literature and recognize our areas of opportunity, and thus be able to make specific changes to improve our results. In addition, these results may serve as a reference for other sites with limited experience in ECMO treatment. All data of mortality in this work happens during ECMO more than after ECMO weaning.

The mortality rates found in our patients are very similar to the majority of those found in a meta-analysis report published in 2013.^[@bibr12-2050312120910353][@bibr13-2050312120910353]--[@bibr14-2050312120910353]^ The main causes of complications and mortality are also very similar to the majority of ECMO reports for these types of patients.^[@bibr15-2050312120910353]^ ECMO is a vital life support tool for patients when all support procedures have failed. However, not all patients are candidates for this therapy. If the pre-existing conditions for ECMO are poor and the possibility of organic recovery in the short term is limited, chances of survival are reduced exponentially. Therefore, proper selection of patients who are candidates for life support with ECMO ensures a greater chance of success and survival.^[@bibr16-2050312120910353],[@bibr17-2050312120910353]^

We find that the average stay in V-A ECMO for patients who survived was almost 4 days, while the average stay of those who died was approximately 9 days. In addition, all patients who remained on ECMO for more than 4 days died.

These data are congruent with a multi-institutional analysis conducted in the United States and published recently where the direct relationship between ECMO stay and mortality was demonstrated.^[@bibr18-2050312120910353]^

Another interesting outcome of this study is that all patients who died had the ECMO set up in the operating room, while patients who had the ECMO set up in the intensive care unit show greater survival. We did not find other studies with similar outcomes, and several authors reported no difference in survival when ECMO setup locations were compared.^[@bibr19-2050312120910353]^

Complications and mortality are closely related, as previously mentioned, and main causes of complications and mortality are also very similar to the majority of ECMO reports for these types of patients.^[@bibr12-2050312120910353]^ Sepsis is, of course, one of the most common complications and preventive measures should be established to reduce this serious condition.^[@bibr20-2050312120910353]^ Another aspect that needs to be closely monitored is renal function to attempt to diminish the occurrence of renal failure.^[@bibr21-2050312120910353]^ Early monitoring of biomarkers for sepsis and renal function should reduce mortality rates. Finally, hemorrhagic events, including cerebral hemorrhage, are very common in ECMO-treated patients,^[@bibr22-2050312120910353]^ and these events may be related to patient condition, disease factors, factors related to the ECMO treatment, or a combination of all of them.^[@bibr23-2050312120910353]^

The main limitation of this study was sample size, but it was impossible to avoid due to the characteristics of the population and the context of the health care services.

Conclusion {#section19-2050312120910353}
==========

In this novel experience with V-A ECMO in pediatric patients post-operated from cardiovascular congenital diseases, we find a survival similar to what is reported globally. The main complications were sepsis, MODS, acute renal failure, and severe cerebral hemorrhage.

The time spent in ECMO is directly related to mortality, and patients who spend more than 4 days in ECMO have a higher likelihood of dying (100%). Patients who have ECMO set up in the operating room have more probabilities of dying than patients who have ECMO set up in intensive care units.
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